Becton, Dickinson and Company (NYSE:BDX) Given New $180.00 Price Target at Argus

Becton, Dickinson and Company (NYSE:BDX) had its target price decreased by equities research analysts at Argus from $230.00 to $180.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Argus’ target price suggests a potential upside of 14.92% from the company’s previous close.

BDX has been the topic of a number of other reports. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research note on Tuesday, February 10th. Citigroup lowered their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. TD Cowen lifted their price objective on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Zacks Research lowered shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Finally, Bank of America upped their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $191.62.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $2.49 during trading on Monday, hitting $156.62. 162,145 shares of the company traded hands, compared to its average volume of 2,824,074. The stock has a market capitalization of $44.60 billion, a price-to-earnings ratio of 25.56, a PEG ratio of 11.17 and a beta of 0.24. The business’s fifty day moving average is $185.53 and its 200-day moving average is $188.82. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter last year, the business posted $3.43 EPS. The business’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,787 shares of company stock worth $551,391. Company insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. SOA Wealth Advisors LLC. lifted its position in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management increased its position in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the period. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $25,000. Steph & Co. raised its stake in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. Finally, SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.